Paulo César Trindade da Costa, Thales Luciano Bezerra Santos, Jaqueline Ferreira Ramos, J. A. M. Santos, F. Medeiros, J. Freitas, W. Oliveira
{"title":"丙基(E)-3-(呋喃-2-基)丙烯酸酯:对白色念珠菌麦角甾醇的生物合成具有调节作用的合成抗真菌潜力","authors":"Paulo César Trindade da Costa, Thales Luciano Bezerra Santos, Jaqueline Ferreira Ramos, J. A. M. Santos, F. Medeiros, J. Freitas, W. Oliveira","doi":"10.1590/s2175-97902023e22045","DOIUrl":null,"url":null,"abstract":"The genus Candida represents the main cause of infections of fungal origin. Some species stand out as disease promoters in humans, such as C. albicans , C. glabrata , C. parapsilosis, and C. tropicalis . This study evaluated the antifungal effects of propyl (E) -3- (furan-2-yl) acrylate. The minimum inhibitory concentration of the synthetic compound, amphotericin B and fluconazole alone against four species of Candida ranged from 64 to 512 μg/mL, 1 to 2 μg/mL, and 32 to 256 μg/mL, respectively. The synergistic effect of the test substance was observed when associated with fluconazole against C. glabrata , there was no antagonism between the substances against any of the tested strains. The potential drug promoted morphological changes in C. albicans , decreasing the amount of resistance, virulence, and reproduction structures, such as the formation of pseudohyphae, blastoconidia, and chlamydospores, ensuring the antifungal potential of this substance. It was also possible to identify the fungicidal profile of the test substance through the study of the growth kinetics of C. albicans . Finally, it was observed that the test compound inhibited the ergosterol biosynthesis by yeast.","PeriodicalId":9218,"journal":{"name":"Brazilian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Propyl (E)-3-(furan-2-yl) Acrylate: a synthetic antifungal potential with a regulatory effect on the biosynthesis of ergosterol in Candida Albicans\",\"authors\":\"Paulo César Trindade da Costa, Thales Luciano Bezerra Santos, Jaqueline Ferreira Ramos, J. A. M. Santos, F. Medeiros, J. Freitas, W. Oliveira\",\"doi\":\"10.1590/s2175-97902023e22045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The genus Candida represents the main cause of infections of fungal origin. Some species stand out as disease promoters in humans, such as C. albicans , C. glabrata , C. parapsilosis, and C. tropicalis . This study evaluated the antifungal effects of propyl (E) -3- (furan-2-yl) acrylate. The minimum inhibitory concentration of the synthetic compound, amphotericin B and fluconazole alone against four species of Candida ranged from 64 to 512 μg/mL, 1 to 2 μg/mL, and 32 to 256 μg/mL, respectively. The synergistic effect of the test substance was observed when associated with fluconazole against C. glabrata , there was no antagonism between the substances against any of the tested strains. The potential drug promoted morphological changes in C. albicans , decreasing the amount of resistance, virulence, and reproduction structures, such as the formation of pseudohyphae, blastoconidia, and chlamydospores, ensuring the antifungal potential of this substance. It was also possible to identify the fungicidal profile of the test substance through the study of the growth kinetics of C. albicans . Finally, it was observed that the test compound inhibited the ergosterol biosynthesis by yeast.\",\"PeriodicalId\":9218,\"journal\":{\"name\":\"Brazilian Journal of Pharmaceutical Sciences\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brazilian Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1590/s2175-97902023e22045\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brazilian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/s2175-97902023e22045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Propyl (E)-3-(furan-2-yl) Acrylate: a synthetic antifungal potential with a regulatory effect on the biosynthesis of ergosterol in Candida Albicans
The genus Candida represents the main cause of infections of fungal origin. Some species stand out as disease promoters in humans, such as C. albicans , C. glabrata , C. parapsilosis, and C. tropicalis . This study evaluated the antifungal effects of propyl (E) -3- (furan-2-yl) acrylate. The minimum inhibitory concentration of the synthetic compound, amphotericin B and fluconazole alone against four species of Candida ranged from 64 to 512 μg/mL, 1 to 2 μg/mL, and 32 to 256 μg/mL, respectively. The synergistic effect of the test substance was observed when associated with fluconazole against C. glabrata , there was no antagonism between the substances against any of the tested strains. The potential drug promoted morphological changes in C. albicans , decreasing the amount of resistance, virulence, and reproduction structures, such as the formation of pseudohyphae, blastoconidia, and chlamydospores, ensuring the antifungal potential of this substance. It was also possible to identify the fungicidal profile of the test substance through the study of the growth kinetics of C. albicans . Finally, it was observed that the test compound inhibited the ergosterol biosynthesis by yeast.
期刊介绍:
The Brazilian Journal of Pharmaceutical Sciences accepts for publication Original Papers applicable to the fields of Pharmaceutical Sciences; Reviews and Current Comment Articles, which are published under the Scientific Editor and Associate Editors invitation to recognized experts or when they are spontaneously submitted by the authors in the form of abstracts to have their importance evaluated. A critical view of the subject with insertions of results of previous works in the field in relation to the state of art must be included; Short Communications reporting new methods and previews of works on researches of outstanding importance in which originality justify a quick publication. A maximum of 2000 words excluding tables, figures and references is an acceptable limit. One table, one figure and ten references may be added, and Book Reviews of the latest editions of books, prepared by specialists invited by the Scientific Editor and Associate Editors. Thematic Supplements as well as those related to scientific meetings can be published under the Scientific Editor and/or Associate Editors agreement.